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Abstract
Purpose:  Acute oral tyrosine administration has been associated with increased constant-load, 
submaximal exercise capacity in the heat.  This study sought to determine whether self-paced 
exercise performance in the heat is enhanced with the same tyrosine dosage.
Methods:  Following familiarisation, seven male endurance-trained volunteers, unacclimated to 
exercise in the heat,  performed two experimental trials  in 30°C (60% relative humidity)  in a 
crossover fashion separated by at least 7 days.  Subjects ingested 150 mg·kg body mass -1 tyrosine 
(TYR) or an isocaloric quantity of whey powder (PLA) in 500 mL of sugar-free flavoured water 
in a randomised, double-blind fashion.  Sixty minutes following drink ingestion subjects cycled 
for 60 min at 57 ± 4% peak oxygen uptake (O2peak), then performed a simulated cycling time-trial 
requiring completion of an individualised target work quantity (393.1 ± 39.8 kJ).
Results:  The  ratio  of  plasma tyrosine  plus  phenylalanine  (tyrosine  precursor):  amino  acids 
competing for brain uptake (free-tryptophan, leucine, isoleucine, valine, methionine, threonine, 
lysine) increased 2.5-fold from rest in TYR, and remained elevated throughout exercise (P < 
0.001), whereas it  declined in PLA from rest  to pre-exercise (P = 0.004).  Time-trial  power 
output (P  = 0.869) and performance (34.8 ± 6.5 min and 35.2 ± 8.3 min in TYR and PLA, 
respectively; P = 0.4167) were similar between trials.  Thermal sensation (P > 0.05), RPE (P > 
0.05), core temperature (P = 0.860), skin temperature (P = 0.822) and heart rate (P = 0.314) did 
not differ between trials.
Conclusion:  These data indicate that acute tyrosine administration did not influence self-paced 
endurance exercise performance in the heat.  Plasma tyrosine availability is apparently not a key 
determinant of fatigue processes under these conditions.
Keywords: amino acids; catecholamines; mild hyperthermia; central fatigue; prolonged exercise
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Introduction 
Exercise  performance  is  clearly  impaired  in  high  ambient  temperature  compared  to  cooler 
conditions  (33).   This  impairment  has been primarily  attributed  to fatigue  caused by central 
nervous  system changes,  secondary  to  increased  brain  temperature  (21),  although  peripheral 
factors  including  high  skin  temperature,  dehydration  and  alterations  in  circulatory  and 
thermoregulatory factors likely also contribute to this (28).  A definitive neurobiological cause 
has yet to be established for this central fatigue but one, or several, neurochemical systems are 
likely to be involved.  There is a well-defined role for the brain catecholamines dopamine and 
noradrenaline in increased motivation, arousal and reward (4), acute stress responses (26), motor 
initiation  and  control  (14)  and  thermoregulation  (9).   Therefore,  it  is  plausible  these 
neurotransmitters modulate the central fatigue associated with prolonged exercise in the heat.  
The amino acid tyrosine is  a nutritional  substrate  precursor for dopamine and noradrenaline. 
Brain tyrosine concentrations are above the Km for tyrosine hydroxylase, the rate-limiting enzyme 
in catecholamine synthesis (8).  Catecholamine synthesis and release is also limited by neuronal 
firing rate so that during periods of low impulse flow tyrosine hydroxylase is highly susceptible 
to catecholamine end-product inhibition (8).  Microdialysis measurements in the rat confirm that 
augmentation  of  cerebral  catecholamine  release  following  systemic  tyrosine  injection,  while 
under basal conditions, is generally limited in magnitude and duration (12).  In animals exposed 
to  extreme  environmental  stress  which  substantially  increases  impulse  flow  through 
catecholamine  neurons,  such  as  nigrostriatal  lesioning,  electrical  stimulation  of  cerebral 
catecholamine pathways or tail-shock, neurotransmitter turnover is elevated and tyrosine may be 
depleted in some neuronal populations (5, 12, 17).  Tyrosine hydroxylase then exhibits increased 
affinity for tyrosine coupled with a decreased sensitivity to catecholamine end-product inhibition 
(27).   Under  these  conditions,  tyrosine  administered  to  rats  by  injection  or  dietary  means 
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maintains cerebral tyrosine levels and augments central nervous system catecholamine turnover 
in activated neuronal populations (17, 32).  Impairments in locomotion, exploratory behaviour, 
memory and coping behaviour in rats exposed to acute, experimentally-induced stress such as 
tail-shock,  heat  or  cold exposure are  also countered by tyrosine  administration  (17,  18,  39). 
There is also a large body of evidence that cognitive, psychomotor and mood impairments and 
symptom intensity in humans induced by demanding environmental  conditions such as cold, 
hypoxia or prolonged wakefulness, are countered by increasing plasma tyrosine availability via 
acute oral administration prior to exposure to the environmental conditions (1, 19, 20).  Evidence 
supporting an enhancement of exercise in humans following acute tyrosine supplementation is 
less clear.  Studies have generally failed to show benefits of acute tyrosine administration on 
exercise  capacity,  exercise  performance,  muscle  strength  and  anaerobic  power  in  temperate 
ambient  conditions  (7,  30,  31).  There  are  mixed  reports  of  the  effectiveness  of  tyrosine 
supplementation prior to prolonged exercise in the heat. One recent study reported improved 
capacity to perform constant-load,  submaximal  intensity exercise in 30°C heat (60% relative 
humidity)  following acute administration of 150 mg·kg body mass-1 tyrosine (34) but a separate 
study using a similar protocol and tyrosine dosage failed to show an effect (35).  
Both Tumilty et al. (34) and Watson et al. (35) reported a marked increase in the ratio of plasma 
tyrosine: neutral amino acids which compete for brain uptake following supplementation.  This 
ratio  is  a  key  determinant  of  brain  uptake  of  a  single  amino  acid  rather  than  the  plasma 
concentration of the amino acid per se, as there are several neutral amino acids competing for a 
shared, saturable carrier molecule across the blood-brain barrier (13). Therefore, increasing the 
plasma concentration of a single amino acid, or the concentration of competing amino acids, will 
increase or decrease the brain uptake of a given amino acid, respectively (13).  
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To date, no study has assessed whether exercise performance (e.g. a time-trial) in the heat is 
augmented by high tyrosine availability despite evidence that tyrosine supplementation counters 
the adverse effects of challenging environmental conditions.  Due to the self-paced nature of a 
performance time-trial, which will be highly influenced by motivation and arousal, it is plausible 
that any improvements following tyrosine supplementation would be more apparent during this 
type of exercise trial compared to a constant-load capacity trial.  Therefore the present study was 
designed  to  test  the  hypothesis  that  acute  tyrosine  administration  would  improve  exercise 
performance in the heat.
Methods
Subjects
Eight  male  volunteers,  unacclimated  to  exercise  in  the  heat,  and  participating  in  regular 
endurance training at least four times per week, gave written informed consent to take part in the 
study.  This sample size provided sufficient power in a previous study to highlight an effect of 
tyrosine supplementation on prolonged exercise capacity in the heat (34).  One subject did not 
complete  testing  due  to  injury  and  the  corresponding  data  was  omitted  from  all  statistical 
analysis.  The remaining seven subjects, classified as Performance level 3 (10), [six competitive 
cyclists and one competitive runner with regular experience of cycling; median age, 20 (range, 
26) years; median stature, 1.83 (range, 0.13) m; mean ± SD for body mass, 77.9 ± 11.7 kg; peak 
oxygen uptake (O2peak),  60 ± 11 mL·kg·min-1; peak power output attained during ramp test on a 
cycle ergometer to elicit O2peak, 389 ± 44 W; maximal heart rate attained during ramp test, 186 ± 
8 beats·min-1] completed all trials.  Testing was carried out between October and June in Wales 
within the UK when the average daytime air temperature typically ranges between 3°C and 17 
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°C.  All subjects were resident here for at least one month before the commencement of testing.  
The study was approved by Aberystwyth University Research Ethics Committee.
Experimental procedures
Subjects visited the lab on five separate occasions: an initial ramp test to determine peak power 
output, maximal heart rate and O2peak using an online breath-by-breath system (Jager Oxycon Pro, 
Hoechberg, Germany); 2 familiarisation visits; and 2 main experimental trials.  No strenuous or 
unaccustomed exercise was permitted for 24 h before each test.  Subjects were instructed to sleep 
for  ≥ 8  h  the  night  before  each  laboratory  visit  to  ensure  they  were  rested,  and  verbal 
confirmation  of adherence  to  this  was given on arrival  for each  test  day.   All  exercise was 
performed  on  an  electrically  braked  cycle  ergometer  (Lode  Excalibur  Sport,  Groningen, 
Netherlands).   Subjects wore comfortable clothing,  which was kept consistent between trials, 
typically consisting of shorts, t-shirt and sports shoes or cycling shorts, short-sleeved cycling top 
and cycling shoes.  During the ramp test, power output was increased at a rate of 0.5 W·s -1 until 
the subject reached volitional exhaustion and O2peak was determined as the highest oxygen uptake 
(O2) averaged over  a 30 s period.   Gas exchange threshold was identified  using the v-slope 
method, determined as the first disproportionate increase in carbon dioxide output (CO2) relative 
to O2 and an increase in the ventilatory equivalent for O2 in relation to a levelling off or continued 
decrease in the ventilatory equivalent for CO2 (2).  Heart rate was recorded continuously during 
all trials using radiotelemetry (Polar RS800CX, Polar Electro Oy, Tampere,  Finland) and the 
peak value measured during the ramp test was recorded as maximal heart rate.  At least 48 h 
elapsed between the ramp test and the first familiarisation visit and at least 7 d separated each of 
the remaining four trials.  The familiarisation visits were designed to appease any anxiety and to 
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allow subjects to become accustomed to the time-trial protocol in the heat.  These visits were 
identical  to  the  main  experimental  trials  except  that  blood  samples  were  not  taken  and the 
placebo drink (see below) was administered for both familiarisations.  All of the familiarisation 
and main trials commenced between 0630 h and 0930 h with each subject performing all four 
trials at the same time of day to control for diurnal variation.  Subjects recorded their food and 
drink intake for 48 h, and physical activity for 24 h, prior to the first familiarisation, and this 
enabled duplication prior to each subsequent visit.  After arriving at the laboratory following an 
overnight fast of at least 8 h, except for 500 mL of ordinary tap water which they drank exactly 2 
h  before  arriving,  subjects  emptied  their  bladder  into  a  pyrex  beaker.   Urine  volume  was 
measured to the nearest mL before a 1.0 mL aliquot was frozen at -80°C for later measurement 
of osomolality, in duplicate, using freezing point depression (Osmostat 030, Gonotec, Berlin). 
Nude, post-void body mass was measured to the nearest 0.1 kg (Seca 645, Seca GMB and Co., 
Hamburg, Germany),  and stature was recorded (Holtain Ltd., stadiometer, Crymych, UK).  A 
rectal thermistor (Grant Instruments, Cambridge, England) was self-positioned by each subject 
10 cm beyond the anal sphincter to enable core temperature measurement (Tcore) and surface 
skin temperature  probes  (Grant  Instruments,  Cambridge,  England)  were attached to  the calf, 
thigh, chest and tricep using breathable medical tape (Hypafix, Bsn Medical, Hull, UK) so skin 
temperature (Tskin) could be measured.  Tcore and Tskin were recorded from an electronic data 
logger (Squirrel SQ2020, Grant Instruments, Cambridge, England) and from these data, mean 
weighted skin temperature was calculated (24).  Subjects were seated for 15 min to minimize the 
effect of plasma volume changes before a 10.5 mL resting blood sample was obtained (Rest),  
with minimal stasis, from an antecubital vein, comprising 6 mL into a heparinised vacutainer and 
4.5  mL into  a  K3EDTA treated  vacutainer  (BD Vacutainer  Systems,  Plymouth,  UK).   The 
experimental  or  placebo  drink  were  administered  in  a  randomised,  double-blind  and 
counterbalanced manner, before subjects were seated in a quiet, comfortable environment (20.5 
AC
CE
PT
ED
Copyright © 2013 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
± 0.4 °C, 44 ± 6% relative humidity)  for 1 h.  The experimental drink (TYR) contained 150 
mg·kg body mass-1 tyrosine (SHS international Ltd., Liverpool, UK) and 7 g vanilla flavouring 
(Myprotein.co.uk, Cheadle, Cheshire,  UK) in 500 mL of fluid [ordinary tap water with 40% 
sugar-free  lemon  and  lime  squash  (Morrisons,  Bradford,  UK)].   This  tyrosine  dosage  was 
associated with increased exercise capacity in the heat in an earlier study (34).  The placebo 
drink  (PLA)  contained  the  same  fluid  volume  and  content,  with  an  isocaloric  quantity  of 
hydrolysed whey protein (Myprotein.co.uk, Cheadle, Cheshire, UK) instead of tyrosine (equating 
to 11.6 ± 1.6 g tyrosine or 6.1 ± 0.8 g whey protein; 22 ± 3 kcal) to ensure any performance 
effects of tyrosine were not due to the additional energy content of the experimental drink.  All 
drinks were coded and prepared by a separate drinks supervisor to ensure they were allocated in 
a double-blind manner.  Prior pilot work with three volunteers, who did not participate in this 
study, confirmed the drinks were indistinguishable in colour, taste and texture.  Care was taken 
to properly blend the mixtures, which were served in opaque drinking bottles, and were shaken 
vigorously immediately before ingestion.  At the end of the 1 h period, a second 10.5 mL blood 
sample (Pre) was taken before subjects  entered the climate chamber (Design Environmental, 
Gwent, Wales).  Temperature and relative humidity of the chamber were maintained at  30.1 ± 
0.2°C, 60 ± 0% respectively,  and mean air velocity within the chamber was 0.26 ± 0.1 m·s -1 
during all trials.  Once inside the chamber, subjects commenced cycling, without a warm up, at a 
constant power output equivalent to 10% Δ [power output requiring a O2 that is 10% of the 
difference between the O2 at the gas exchange threshold and O2peak (16); 156 ± 24 W or 57 ± 4% 
O2peak  in this  subject group] for 60 min.   The purpose of this  exercise period was to  induce 
hyperthermia  before  commencement  of  the  time  trial.   No  information  on  time  elapsed  or 
motivational encouragement was given to the subjects throughout this exercise period.  Drinks (2 
mL·kg  body  mass-1  ordinary  tap  water  with  20%  sugar-free  lemon  and  lime  squash)  were 
provided at 15, 30, 45 and 59 min.  At the end of the 60 min of cycling subjects were quickly 
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removed to a chair directly adjacent to the cycle ergometer within the climate chamber, where a 
further  10.5  mL blood sample  was  obtained  (Post  60).   Subjects  then  remounted  the  cycle 
ergometer to perform a simulated cycling time-trial.   A maximum of 2 min elapsed between 
subjects dismounting the ergometer and the acquisition of the Post 60 blood sample.  The time 
taken to obtain this  sample,  and the time between the end of the 60 min of cycling and the 
commencement of the time-trial, was standardised for each individual subject during subsequent 
trials. 
The time-trial was based on a validated protocol used in previous research examining fatigue 
during prolonged exercise in the heat (36), and requires subjects to complete a set amount of 
work as quickly as possible.  Individual target work quantities were calculated for each subject as 
the amount of work which would be completed during 30 min cycling at 60% of the power 
output eliciting O2peak  during the initial  ramp test (393.1 ± 39.8 kJ in this group).  The cycle 
ergometer was set in linear mode (workload increases as pedalling rate increases) during the 
time-trial  so  that  the  power  output,  and  hence  the  completed  work,  was  directly  related  to 
pedalling cadence.  At the start of the time-trial subjects were given their target work quantities 
and instructed to complete  the required amount of work as quickly as possible and no other 
instructions or motivational encouragement was given throughout.  The control console for the 
ergometer was positioned on the bike frame, and the display was masked with non-transparent 
adhesive tape so that only the cumulative work portion of the console display was visible.  No 
further feedback on power output, cadence or time elapsed was provided throughout the time-
trial.  A cumulative work target was also taped to the front of the ergometer handlebars, in full  
view of the subjects, which detailed the required work to achieve 25%, 50%, 75%, and 100% of 
their  individual  target.   Subjects were permitted to drink  ad-libitum throughout (ordinary tap 
water with 20% sugar-free lemon and lime squash).  On completion of the time-trial subjects 
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dismounted the cycle ergometer,  moved quickly to the adjacent chair where a final 10.5 mL 
blood sample  (Post  TT)  was obtained  within a  maximum of  2 min,  and this  time  was also 
standardised for each individual subject during subsequent trials.  Subjects emptied their bladder, 
urine volume was again recorded to the nearest mL before a 1.0 mL aliquot was removed, then 
frozen at -80°C for later osmolality measurement. Finally, the thermistor and skin probes were 
removed before subjects showered, towelled dry and then were reweighed nude.
Physiological measurements and blood analysis
Heart rate, Tcore and Tskin were recorded every 10 min throughout 60 min rest and 60 min of 
submaximal exercise.  Power output, heart rate, Tcore and Tskin were recorded at the start of the 
time-trial, and every 5 min throughout exercise.  RPE (3) and thermal sensation, using a 21 point  
scale ranging from -10 (cold impossible to bear) to +10 (heat impossible to bear) (adapted from 
22), were recorded every 10 min throughout 60 min submaximal exercise, after 5 min of the 
time-trial had elapsed, and then every 5 min throughout the time-trial.  One minute expired gas 
samples were collected in Douglas bags at  30 min and 50 min of the constant-load exercise 
period.   Oxygen  and  carbon  dioxide  concentrations  were  measured  using  a  combined 
paramagnetic  oxygen  analyser  and  infrared  carbon  dioxide  analyser  (Series  4100  Xentra, 
Servomex, Crowborough, UK), which were calibrated before each trial using commercial gases 
(BOC,  Guildford,  UK),  and expired  volume was  measured  using  a  dry gas  meter  (Harvard 
Apparatus Ltd., Edenbridge, UK).  Expired gases were used to estimate fat and carbohydrate 
utilisation and energy expenditure  (23).  Final measurements of heart rate, Tcore, Tskin, RPE, 
thermal sensation, and power output were recorded immediately before subjects completed the 
time-trial.  Wind speed within the chamber was measured every 15 min of exercise as the mean 
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value of four measurements taken from in front, behind, and to the left and right of each subject 
at head height while seated on the cycle ergometer, using a hand held anemometer (Kestrel 1000, 
Richard Paul Russell Ltd, Lymington, UK).  
Blood from the K3EDTA vacutainer was used to measure haematocrit, haemoglobin, lactate and 
glucose.  Whole blood was drawn into micro-capillary tubes, spun for 5 min at 14000 g using a 
Hawksley microcentrifuge (Haematospin 1400, Hawksley, Lancing, UK) and the separated red 
cell  volume was measured  using  a  Hawksley haematocrit  tube  reader,  with  a  coefficient  of 
variation  of  0.8%  for  10  repeated  measurements  on  the  same  sample.   Haemoglobin  was 
measured using an automated haematology analyser (Pentra 60C +, Horiba ABX Diagnostics, 
Northampton, UK), with a coefficient of variation of 0.3% for 10 repeated measurements on the 
same  sample  standard,  containing  14.0  g·L-1 haemoglobin.    Haematocrit  and  haemoglobin 
measurements were used to estimate plasma volume changes (11).  Blood glucose and blood 
lactate  concentrations  were  measured  using  an  automated  analyser  (2300  Stat  Plus,  Yellow 
Spring Instrument Co., Ohio, USA), calibrated with standard concentrations for glucose (0.00, 
and 50.00 mmol·L-1) and lactate (0.00 and 30.00 mmol·L-1).  The coefficient of variation for 10 
repeated measurements on a sample standard for blood glucose (6.14 mmol·L-1) and blood lactate 
(5.35  mmol·L-1)  is  1.7%  and  1.5%,  respectively.   The  heparinised  blood  was  immediately 
centrifuged at 1500 g for 10 minutes at 4°C, the plasma was then separated, and stored at -80°C 
for  later  analysis  of  amino  acids  using  gas  chromatography  mass  spectrometry  (34).  The 
coefficient  of  variation  for  the  measurement  of  individual  plasma  amino  acids  using  this 
technique is: leucine, 8.5%; isoleucine, 9.7%; valine, 5.8%; methionine, 11.4%; threonine, 8.7%; 
lysine,  5.0%; the free fraction of tryptophan unbound from albumin (free-tryptophan),  5.2%; 
phenylalanine,  7.5%  and  tyrosine,  6.5%.  Haematocrit  was  measured  in  triplicate  and  all 
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remaining blood analyses were measured in duplicate. All blood parameters were corrected for 
plasma volume changes from baseline measurements at Rest.  
Statistical analyses
A computerized statistical package was used to analyse all data (SPSS version 17.0, SPSS inc., 
Chicago, IL).  Normally distributed data are presented as mean ± SD.  Time trial performance, 
urine  osmolality  and rate  of  body mass  losses  were  examined  using  Student’s  paired  t-test. 
Cohen’s  d effect  size  was  calculated  for  the  difference  in  time  to  complete  the  time-trial. 
Differences in data throughout trials were compared using a repeated measures 2 factor (time × 
trial)  analysis  of  variance  (ANOVA).   Where  significant  differences  were  found,  post  hoc 
analysis was carried out using Student’s paired  t-tests with the Bonferroni correction.  End of 
time-trial  values  were  analysed  separately  using  Student’s  paired  t-test  to  account  for  the 
different  exercise  duration  between  subjects  and  trials.   Non-normally  distributed  data  are 
presented as median (range), were analysed using Friedman’s tests, and where appropriate, post  
hoc tests were carried out using Wilcoxon matched pairs tests with the Bonferroni correction. 
Statistical significance was set at P < 0.05.
Results
Time-trial performance
Following completion of all  trials,  three subjects reported they felt  better  or more motivated 
during  the  tyrosine  trial,  but  could  not  distinguish  between  the  TYR and  PLA drinks,  two 
subjects  incorrectly  thought  they  had  received  PLA when  they  had  received  TYR,  and  the 
remaining two subjects were unable to distinguish between trials, indicating successful drinks-
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blinding.   The  coefficient  of  variation  for  time  to  complete  the  time-trial  between  the  2nd 
familiarisation trial and the PLA trial was 1.3% and there was no effect of trial order during the 
experimental trials (P = 0.313).  TYR did not influence the time to complete the time-trial (P = 
0.417; 34.8 ± 6.5 min in TYR and 35.2 ± 8.3 min in PLA; Fig. 1A) and power output throughout 
the time-trial was similar in both trials (P = 0.869; Fig. 1B).  The effect size for TYR versus PLA 
is calculated as 0.05 and the resultant statistical power value is 0.11.  A SD of 0.6 would be 
required to detect significant differences in time trial performance between TYR and PLA with 7 
subjects  per  group,  yielding  an  estimated  statistical  power  value  of  0.80  (P =  0.05;  37). 
Subjects’  performance  was  even-paced  up  to  20  min  of  the  time-trial  (P =  0.061),  which 
represented the last time-point at which all subjects were still exercising.
Blood analysis
Plasma tyrosine concentration at Rest was similar in both trials (P = 0.269; Fig. 2A), but was 
higher in TYR at all remaining sampling times (P < 0.01), while the concentration remained 
unchanged from Rest in PLA (P > 0.05).  Plasma phenylalanine concentration was unchanged at 
any time-point  in TYR (P > 0.05) but was elevated from Rest in PLA on completion of the time-
trial  (P < 0.01).  There was no difference between trials  in the ratio  of plasma tyrosine plus 
phenylalanine:  Σ(free-tryptophan; valine,  leucine,  isoleucine,  threonine,  methionine,  lysine)  at 
Rest (P = 0.838; Fig. 2B) but the ratio was higher in TYR at all other time-points (P = 0.001). 
TYR ingestion increased this ratio over 2.5-fold (P < 0.001) from Rest and remained elevated at 
all other sampling times (P < 0.001).  In PLA, there was a transient decline in this ratio from 
Rest to Pre-exercise (P = 0.004).  The plasma concentrations of the remaining individual amino 
acids analysed are provided in Table 1.  Blood glucose concentration was unaffected by drink 
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ingested (P > 0.05) or exercise (P = 0.801) and was 5.3 ± 0.9 mmol·L-1 in both trials at Post TT. 
At Post  60,  blood lactate  concentration  had increased  from Rest  in  both trials  (P = 0.018), 
remaining elevated from Rest at Post TT (P = 0.018), but did not differ between trials [P > 0.05; 
3.2  (range,  3.6)  mmol·L-1 in  TYR and 4.1  (range,  4.9)  mmol·L-1 in  PLA].   Plasma  volume 
progressively declined, and to a similar extent in both trials, following drink ingestion (P < 0.05) 
reaching -8.4 ± 6.0% in TYR and -9.1 ± 4.5% in PLA at end of time-trial.  
Temperature measurements
Exercise caused a gradual increase in Tcore (P = 0.003) at a similar rate in both trials (P = 0.131; 
Fig. 3A).  At the end of the time-trial Tcore was 39.0 ± 0.7°C in TYR and 38.9 ± 0.6 in PLA (P 
= 0.474).  Tskin also increased during exercise (P = 0.012), plateauing after 20 min of constant-
load exercise and after 15 min of time-trial (Fig. 3B).  The drink ingested had no influence on 
Tskin (P = 0.822) and there was no difference between trials in Tskin at end of the time-trial 
(34.8 ± 0.8°C in TYR and 35.0 ± 1.3°C in PLA; P = 0.575).  
Heart rate
There was a gradual increase in heart rate throughout exercise (Fig. 4;  P < 0.001) which was 
unaffected by drink ingested (P = 0.314).  At end of the time-trial heart rate reached 100 ± 4% 
and 99 ± 4% of maximum in TYR and PLA, respectively (P = 0.729).
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Urine analysis, fluid intake and body mass losses
Pre-exercise urine osmolality suggested that subjects were similarly hydrated before both trials 
(P = 0.571; 329 ± 136 mosmol·kg-1 in TYR and 369 ± 148 mosmol·kg-1 in PLA). After the time-
trial urine osmolality was similar in each trial (198 ± 56 mosmol·kg -1  in TYR and 325 ± 296 
mosmol·kg-1 in PLA; P = 0.218) and unchanged from pre-exercise (P = 0.202).  Subjects drank 
similar volumes of fluid during the time-trial in both trials (311.1 ± 114.4 mL in TYR and 363.0 
± 126.1 mL in PLA; P = 0.415).  By the end of the time-trial body mass losses, calculated from 
the difference  between pre-  and post-exercise  body mass  adjusted for  fluid intake  and urine 
output following initial weighing (2.9 ± 0.7% and 3.1 ± 1.1% of pre-exercise body mass in TYR 
and PLA, respectively; P = 0.528), and the rate of body mass loss (P = 0.436; 4.0 ± 1.0 kg·h-1 in 
TYR and 4.3 ± 1.6 kg·h-1 in PLA) were similar in both trials.
Subjective ratings
Expressed RPE gradually increased throughout exercise (Fig. 5A).  There was no difference in 
RPE between trials at any time-point  (P > 0.05).  Median RPE at end of the time-trial was 19 
(range,  3)  arbitrary units  in  both trials  (P =  0.689).   Thermal  sensation  gradually  increased 
throughout exercise (Fig. 5B) and was the same in TYR and PLA throughout exercise (P > 0.05). 
Median ratings at end of the time-trial were 7 (range, 5) arbitrary units in TYR, representing a 
rating between “Very hot, uncomfortable” and “Extremely hot, close to limit”.  Median thermal 
sensation at end of the time-trial in PLA was similar to TYR (P = 0.276), and was 8 (range, 6) 
arbitrary units representing a rating of “Extremely hot, close to limit”. 
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Estimated substrate usage
Estimated fat (P = 0.253) and carbohydrate (P = 0.290) oxidation rates and estimated energy 
expenditure  (P =  0.200)  were  unchanged  from 30  to  50  min  of  constant-load  submaximal 
exercise, and were similar in both trials (P > 0.05).  
Discussion
Previous studies have examined the effect of tyrosine administration on exercise capacity in the 
heat in man (34, 35), but this is the first study to examine self-paced exercise performance in the 
heat following acute oral tyrosine administration.  The present results demonstrate that, contrary 
to  the  hypothesis,  acute  administration  of  tyrosine  did  not  improve  self-paced  exercise 
performance in the heat compared to a placebo containing an isocaloric quantity of hydrolysed 
whey protein.  
It was hypothesized that additional availability of tyrosine, a nutritional catecholamine precursor, 
would enhance exercise tolerance in the heat, as reported in an earlier study adopting a constant-
load  submaximal  intensity  exercise  protocol  (34).   Additionally,  it  was  expected  that  any 
performance  effect  of  tyrosine  administration  would  be  more  pronounced  during  a  variable 
intensity time-trial,  where subjects could self-pace the exercise and thus the subjective effort, 
compared to a constant-load trial.   The similar power output profiles in each time-trial in the 
present study, and therefore similar time to complete a set amount of work irrespective of drink 
ingested, suggests that tyrosine has no performance enhancing effect under the conditions of the 
present  study.   This  occurred  despite  a  sound neurochemical  basis  for  a  benefit  of  tyrosine 
administration prior to performance of a time-trial in the heat.  The clear impairment in exercise 
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performance carried  out  in warm compared to  cooler  ambient  temperature  (33)  seems to be 
caused, in part, by alterations in cerebral function, caused by high brain temperature, resulting in 
reduced voluntary activation of muscle, increased subjective effort and a reduced will or “drive” 
to exercise (21).  Changes in central catecholamine activity are implicated in these processes due 
to their intrinsic connection with increased arousal and motivation (4), thermoregulation (9, 15) 
and motor initiation and control (14).  Additionally,  pharmacological augmentation of central 
catecholamine  activity,  via  acute  bupropion  administration,  improves  simulated  time-trial 
performance  in  the  heat  (30°C)  but  not  in  cooler  conditions  (18°C)  (36),  highlighting  the 
importance of cerebral catecholamine activity in the ability to tolerate exercise with heat stress. 
As tyrosine is a general catecholamine precursor, the experimental drink may have augmented 
central  noradrenaline  activity  and  this  may  offer  partial  explanation  for  the  present  results. 
Recent work has reported an impairment in time trial performance in the heat following acute 
administration of a noradrenaline reuptake inhibitor, reboxetine, compared to a lactose placebo 
(25).   Enhanced noradrenaline activity in the present study following tyrosine administration 
may have constrained any performance effect during the simulated time trial.
The current protocol was employed on the basis that the combination of exercise and heat stress 
would represent a suitably demanding environment such that catecholamine neuronal sensitivity 
would be up-regulated to precursor availability.  The absence of effect on exercise performance 
in the present study occurred despite striking differences between the plasma amino acid profiles 
between trials following drink ingestion.  The marked increase in the ratio of plasma tyrosine 
plus phenylalanine: amino acids competing for brain uptake following tyrosine administration 
was similar in magnitude to one study in which exercise capacity in the heat was prolonged by 
15%, 1 hour  following administration  of  150 mg·kg-1 tyrosine  (34).   This  would  favour  the 
transport of tyrosine into the brain at the expense of other neutral amino acids which compete for 
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uptake at the blood-brain barrier (13).  This plasma ratio transiently declined following ingestion 
of the placebo mixture in the present study which would reduce brain entry of tyrosine (13).  
At least one other study examining tyrosine administration prior to prolonged exercise in the heat 
provides support for the idea that exercise tolerance in the heat is enhanced following prior oral 
tyrosine  administration  (34).   But  a  separate  study employing a  similar  tyrosine  dosage and 
exercise  protocol  reported  no  effect  (35).   It  is  not  entirely  clear  why there  are  discrepant 
findings  between  the  present  study  and  previous  work  reporting  benefit  of  tyrosine 
administration prior to exercise in the heat (34).   This could be related to the degree of arousal 
and stress induced by the different protocols adopted, and therefore the degree of activation of 
the  central  catecholaminergic  system,  and  the  factors  involved  in  the  regulation  of  tyrosine 
hydroxylase and catecholamine synthesis described above.  This may also explain why studies 
examining acute tyrosine administration in man prior to exercise in temperate conditions, have 
largely  failed  to  report  beneficial  effects  on  exercise  capacity  (30),  simulated  time-trial 
performance performance (7) or muscle strength and anaerobic endurance (31).  While it seems 
apparent that, in man, exercise alone in the absence of heat stress is insufficiently demanding to 
up-regulate  catecholamine  precursor  demand  (7,  30),  this  does  not  adequately  explain  the 
discrepant findings between two studies adopting similar prolonged exercise protocols in the heat 
and tyrosine dosage (34, 35) and the underlying reasons for this require further clarification. 
Perhaps the adoption of a range of tyrosine doses in future work, particularly higher doses than 
administered in the present study, may identify whether there is an optimal dose which enhances 
prolonged exercise in the heat.
As already mentioned, high brain catecholaminergic activity is associated with increased arousal 
and  motivation  (4)  therefore  an  augmentation  of  central  catecholamine  following  tyrosine 
administration might be expected to highlight differences in the power output profiles during the 
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time-trial or the subjective response to exercise.  By definition, a self-paced time-trial allows the 
power output throughout the time-trial and thus the relative metabolic demand to be controlled 
from moment-to-moment.   The time-trial  power output data in the present study suggest that 
subjects  adopted  an  even-paced  strategy  throughout  the  first  20  min  of  the  time-trial, 
representing the last  common time-point at  which all  subjects  were still  exercising,  and that 
plasma tyrosine availability did not affect this pacing strategy.  Some investigators suggest that 
the adoption of a pacing strategy is necessary for the avoidance of catastrophic failure of the 
organism (29).  This is hypothesized to involve feedback and feed-forward control mechanisms 
in which the brain processes efferent neural commands based on previous experience of similar 
situations,  in order to elicit  the most appropriate power output and metabolic rate (29).  The 
present power output data demonstrate that even if a subconscious anticipation of the exercise 
power output was adopted, tyrosine had no additional effect on this compared to an isocaloric 
quantity  of  whey  protein.   Furthermore,  the  present  data  suggests  that  the  subjective 
interpretation of the exercise cannot be manipulated by a plasma amino acid profile, following 
ingestion of the experimental mixture, which would favour increased brain uptake of a direct 
catecholamine precursor (13).  
In  summary,  there  was  no  effect  of  acute  tyrosine  administration  on  simulated  time-trial 
performance in the heat compared to a placebo containing an isocaloric quantity of whey protein. 
The lack  of  an association  between increased  tyrosine  availability  and exercise  performance 
suggests  that,  under  the  conditions  of  the  present  study,  acutely  increasing  plasma  tyrosine 
availability  does  not  influence  fatigue  processes  when  self-paced  endurance  exercise  is 
performed with heat stress.
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FIGURE 1—Mean ± SD (columns and vertical error bars) and individual (remaining individual 
lines) times to complete simulated cycling time-trial (A) and power output during time-trial, up 
to the last time point all subjects were exercising and value recorded at end of time-trial (B), in 
tyrosine (TYR) and placebo (PLA) trials.  Data are expressed as mean ± SD, (n = 7). 
FIGURE 2—Changes in plasma tyrosine concentration (A), tyrosine ratio [plasma concentration 
ratio  of  tyrosine  plus  phenylalanine:  Σ(f-tryptophan;  valine,  leucine,  isoleucine,  threonine, 
methionine,  lysine)  (B)  in  tyrosine  (TYR)  and  placebo  (PLA)  trials.   TT,  time-trial. 
##Significant difference between trials, ††significantly different versus Rest in TYR, (P < 0.01); 
§significantly different versus Rest in PLA, (P < 0.05). Data are expressed as mean ± SD, (n = 
7).  
FIGURE 3—Core temperature (A) and mean weighted skin temperature (B) responses during 1 
h rest, 60 min of constant-load submaximal exercise and simulated cycling time-trial (TT), up to 
the last time point that all subjects were exercising and value recorded at end of TT,  in tyrosine 
(TYR) and placebo (PLA)  trials.  **Significantly different versus start value in both trials, (P < 
0.01).  Data are expressed as mean ± SD, (n = 7).  
FIGURE 4—Heart rate responses during 1 h rest, 60 min of constant-load submaximal exercise 
and simulated cycling time-trial (TT), up to the last time point that all subjects were exercising 
and value recorded at end of TT, in tyrosine (TYR) and placebo (PLA) trials. **Significantly 
different versus start value in both trials, (P < 0.01).  Data are expressed as mean ± SD, (n = 7).   
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FIGURE  5—RPE  (A)  and  thermal  sensation  ratings  (B)  during  60  min  of  constant-load 
submaximal  cycling  and simulated  cycling  time-trial  (TT),  up to  the  last  time  point  that  all 
subjects were exercising and value recorded at end of TT,  in tyrosine (TYR)  and placebo (PLA) 
trials.  *Significantly different versus 10 min rating in both trials, (P < 0.05).  Data are expressed 
as mean ± SD, (n = 7).
TABLE 1—Plasma amino acid concentrations in tyrosine (TYR) and placebo (PLA) trials.
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Figure 2
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Figure 3
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Figure 4
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Figure 5
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Table 1
TYR PLA
Rest Pre- Post 60 Post TT Rest Pre- Post 60 Post TT
Amino acids (µmol·L-1)
f-Tryptophan 149 (107) 152 (28) 150 (77) 162 (127) 155 (93) 160 (49) 154 (93) 172 (77)
Valine 158 (69) 135 (51) 159 (81) 143 (73) 165 (85) 166 (53) 144 (102) 161 (108)
Leucine 146 (74) 105 (79)§ 130 (89) 131 (117) 154 (128) 181 (83)# 135 (115) 166 (84)
Isoleucine 83 (42) 66 (38)§ 62 (35) 73 (43) 77 (75) 97 (42)# 76 (55) 86 (29)#
Threonine 92 (46) 99 (58) 96 (44) 92 (68) 120 (45) 118 (54) 104 (51) 121 (55)
Methionine 30 (9) 27 (9) 28 (9) 34 (22)  30 (9) 30 (7)# 31 (144) 36 (15)§
Lysine 254 (115) 251 (131) 216 (98) 215 (178) 226 (161) 276 (139) 253 (147) 246 (112)
Σ (mmol·L-1) 1.0 (0.4) 1.0 (0.3) 0.9 (0.3) 1.0 (0.3) 0.9 (0.3) 0.8 (0.3)# 0.9 (0.3) 0.8 (0.5)
Values are median (range). f-Tryptophan, free tryptophan; Σ, Σ(valine, leucine, isoleucine, threonine, methionine, lysine).  §significantly 
different from Rest in same trial, (P < 0.05; n = 7);  #Significant difference between trials, (P < 0.05; n = 7).
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